Responses

Download PDFPDF
Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses [https://authors.bmj.com/after-submitting/rapid-responses/].
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses [https://www.bmj.com/company/journals-terms-and-conditions-for-rapid-responses/] and understand that your personal data will be processed in accordance with those terms and our privacy notice [https://www.bmj.com/company/your-privacy/].
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Classification Of Diabetic Macular Odema Using Ultra- Wide field angiography and implications for response to anti-VEGF therapy
    • Prathima Musunuru, Senior Resident Department of Ophthalmology, Sri Sathya Sai Institute Of Higher Medical Sciences, Prasanthi Gram, Puttaparthi, Andhra Pradesh.
    • Other Contributors:
      • Anuj Sharma, Consultant

    Dear Sir,
    We read the article "Classification of diabetic macular odema using ultra-widefield angiography and implications for response to anti-VEGF therapy" by Xue K, et al1 with great interest. The authors aimed to classify Diabetic macular odema [DMO] using ultra-widefield flourescein angiography [UWFA] and evaluate response to anti-vascular endothelial growth factor [anti-VEGF]. They concluded that UWFA facilitates detection of peripheral ishemia. DMO group with significant peripheral ishemia responded well to anti-VEGF therapy than other groups. We congratulate the author for their lightening study about subject and would like to make some contributions about study.
    The study did not mention the severity of diabetes of the patients enrolled in the study nor systemic comorbid conditions like glycemic control, systolic hypertension, protinuria1, which would alter the incidence of macular odema.2, 3
    The study selected patients with DMO who have been given subthreshold micropulse diode laser. As it was not mentioned in the study, we wonder if the study desires to see the response of anti-VEGF in non-resolving macular odema patients alone. Also, it was to our surprise why patients with Panretinal photocoagulation were not excluded from the study while classifying the patients into 3 groups .
    The classification of DMO into three groups was not clearly satisfying because there would be always a component of ishemia overlapping between t...

    Show More
    Conflict of Interest:
    None declared.